Search research articles
Contact Us
Filters
Showing results (111-120 of 226) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
The Oncologist
|
July 9, 2011
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice
Charles D Blanke, Richard M Goldberg, Axel Grothey, et al.
Journal of Comparative Effectiveness Research
|
August 24, 2021
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in <i>ROS1</i>+ NSCLC
Robert C Doebele, Laura Perez, Huong Trinh, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 14, 2003
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
Salvatore Cortellino, David Turner, Valeria Masciullo, et al.
Clinical Colorectal Cancer
|
July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
Daniel J Freeman, Todd Juan, Maureen Reiner, et al.
Pancreas
|
July 31, 2008
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
Steven J Cohen, R Katherine Alpaugh, Irma Palazzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer
Sharon L Manne, Neal J Meropol, David S Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Cancer
|
August 14, 2002
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma
Stephen B Edge, Karen Gold, Christine D Berg, et al.
International Journal of Gastrointestinal Cancer
|
September 14, 2004
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome
Aaron R Sasson, R Wesley Wetherington, John P Hoffman, et al.
Page
of 23
Search research articles
Search
Showing results (111-120 of 226) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
The Oncologist
|
July 9, 2011
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice
Charles D Blanke, Richard M Goldberg, Axel Grothey, et al.
Journal of Comparative Effectiveness Research
|
August 24, 2021
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in <i>ROS1</i>+ NSCLC
Robert C Doebele, Laura Perez, Huong Trinh, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 14, 2003
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
Salvatore Cortellino, David Turner, Valeria Masciullo, et al.
Clinical Colorectal Cancer
|
July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
Daniel J Freeman, Todd Juan, Maureen Reiner, et al.
Pancreas
|
July 31, 2008
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
Steven J Cohen, R Katherine Alpaugh, Irma Palazzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer
Sharon L Manne, Neal J Meropol, David S Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Cancer
|
August 14, 2002
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma
Stephen B Edge, Karen Gold, Christine D Berg, et al.
International Journal of Gastrointestinal Cancer
|
September 14, 2004
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome
Aaron R Sasson, R Wesley Wetherington, John P Hoffman, et al.
Page
of 23